Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2006 | 1 |
2018 | 1 |
2019 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Endothelin receptor antagonists for pulmonary arterial hypertension.
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004434. doi: 10.1002/14651858.CD004434.pub3.
Cochrane Database Syst Rev. 2006.
PMID: 16856046
Updated.
Review.
Pulmonary arterial hypertension can be classified into five categories according to Venice classification: (1) Idiopathic PAH; (2) Familial PAH; (3) PAH associated with collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, HIV infection, drugs a …
Pulmonary arterial hypertension can be classified into five categories according to Venice classification: (1) Idiopathic PAH; (2) Familial …
Use of vasodilators for the treatment of pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: A systematic review.
Ogawa A, Sakao S, Tanabe N, Matsubara H, Tatsumi K.
Ogawa A, et al.
Respir Investig. 2019 Mar;57(2):183-190. doi: 10.1016/j.resinv.2018.10.004. Epub 2018 Nov 23.
Respir Investig. 2019.
PMID: 30473253
However, in patients with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis (PVOD/PCH), rare diseases that cause pulmonary hypertension, the effectiveness and safety of vasodilators, including PAH-targeted drugs, are unclear. ...
However, in patients with pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis (PVOD/PCH), rare diseases that cau …
Item in Clipboard
Cite
Cite